Bicycle Therapeutics PLC (NASDAQ:BCYC) has coverage initiated with a Buy rating

Analyst Ratings For Bicycle Therapeutics PLC (NASDAQ:BCYC)

Story continues below

Today, Jefferies Financial Group initiated coverage on Bicycle Therapeutics PLC (NASDAQ:BCYC) with a Buy.

There are 3 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Bicycle Therapeutics PLC (NASDAQ:BCYC) is Buy with a consensus target price of $22.00 per share, a potential 67.94% upside.

Some recent analyst ratings include

  • 6/17/2019-Bicycle Therapeutics PLC (NASDAQ:BCYC) has coverage initiated with a Buy rating
  • 6/17/2019-Bicycle Therapeutics PLC (NASDAQ:BCYC) has coverage initiated with a Neutral rating
  • 6/17/2019-Bicycle Therapeutics PLC (NASDAQ:BCYC) has coverage initiated with a Overweight rating
  • 6/17/2019-Bicycle Therapeutics PLC (NASDAQ:BCYC) has coverage initiated with a Buy rating and $22.00 price target

    Recent Trading Activity for Bicycle Therapeutics PLC (NASDAQ:BCYC)
    Shares of Bicycle Therapeutics PLC closed the previous trading session at 13.10 up +0.70 5.65% with shares trading hands.

    An ad to help with our costs